Compare first-generation and second-generation antihistamines in terms of CNS penetration and typical clinical use.

Compare first-generation and second-generation antihistamines in terms of CNS penetration and typical clinical use.

• A. First-generation cross the blood–brain barrier causing sedation; second-generation minimal CNS penetration, longer duration.
• B. First-generation antihistamines do not cross the blood–brain barrier.
• C. Second-generation antihistamines cause more sedation.
• D. Both generations have the same CNS effects.

Answer: (A)

CNS penetration by antihistamines shapes both their sedative effects and how they’re used clinically. First-generation antihistamines are lipophilic and cross the blood–brain barrier readily, so they block H1 receptors in the brain and produce noticeable sedation and often anticholinergic effects. This makes them useful in some situations where a sedative effect is desired, such as short-term sleep aid or antiemetic use, but it also means daytime drowsiness and cognitive effects can limit daily functioning. Second-generation antihistamines are designed to limit CNS entry. They are less lipophilic and are often pumped out of the brain by P-glycoprotein at the blood–brain barrier, resulting in minimal CNS penetration. This reduces sedation and anticholinergic side effects, and their pharmacokinetics tend to provide longer, more predictable duration of action with typically once-daily dosing, making them preferable for chronic allergic rhinitis and urticaria. So the best restatement is that first-generation agents cross into the CNS and cause sedation, while second-generation agents stay mostly out of the CNS and are used for non-sedating, longer-acting allergy treatment.

CNS penetration by antihistamines shapes both their sedative effects and how they’re used clinically. First-generation antihistamines are lipophilic and cross the blood–brain barrier readily, so they block H1 receptors in the brain and produce noticeable sedation and often anticholinergic effects. This makes them useful in some situations where a sedative effect is desired, such as short-term sleep aid or antiemetic use, but it also means daytime drowsiness and cognitive effects can limit daily functioning.

Second-generation antihistamines are designed to limit CNS entry. They are less lipophilic and are often pumped out of the brain by P-glycoprotein at the blood–brain barrier, resulting in minimal CNS penetration. This reduces sedation and anticholinergic side effects, and their pharmacokinetics tend to provide longer, more predictable duration of action with typically once-daily dosing, making them preferable for chronic allergic rhinitis and urticaria.

So the best restatement is that first-generation agents cross into the CNS and cause sedation, while second-generation agents stay mostly out of the CNS and are used for non-sedating, longer-acting allergy treatment.